Evidence map›Paper›PMID 26292315›Full record

ArticleJournal of clinical microbiology2015

Standardization of Quantitative PCR for Human T-Cell Leukemia Virus Type 1 in Japan: a Collaborative Study.

Madoka Kuramitsu, Kazu Okuma, Tadanori Yamochi, Tomoo Sato, Daisuke Sasaki, Hiroo Hasegawa, Kazumi Umeki, Ryuji Kubota, Rieko Sobata, Chieko Matsumoto and 28 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of clinical microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors at 16 institutions in 1 country.

Madoka KuramitsuDepartment of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, Japan.ORCID http://orcid.org/0000-0002-3064-5219
Kazu OkumaDepartment of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, Japan.
Tadanori YamochiDepartment of Medical Genome Sciences, Laboratory of Tumor Cell Biology, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
Tomoo SatoDepartment of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan.
Daisuke SasakiDepartment of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Hiroo HasegawaDepartment of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Kazumi UmekiDepartment of Rheumatology, Infectious Diseases and Laboratory Medicine, University of Miyazaki, Miyazaki, Japan.
Ryuji KubotaDivision of Molecular Pathology, Center for Chronic Viral Diseases, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
Rieko SobataCentral Blood Institute, Blood Service Headquarters, Japanese Red Cross Society, Tokyo, Japan.
Chieko MatsumotoCentral Blood Institute, Blood Service Headquarters, Japanese Red Cross Society, Tokyo, Japan.
Noriaki KanekoDepartment of Special Testing, SRL Inc., Tokyo, Japan.
Isao NaruseDepartment of Special Testing, SRL Inc., Tokyo, Japan.
Makoto YamagishiDepartment of Medical Genome Sciences, Laboratory of Tumor Cell Biology, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
Makoto NakashimaDepartment of Medical Genome Sciences, Laboratory of Tumor Cell Biology, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
Haruka MomoseDepartment of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, Japan.
Kumiko ArakiDepartment of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, Japan.
Takuo MizukamiDepartment of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, Japan.
Saeko MizusawaDepartment of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, Japan.
Yoshiaki OkadaDepartment of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, Japan.
Masaki OchiaiDepartment of Quality Assurance and Radiological Protection, National Institute of Infectious Diseases, Tokyo, Japan.
Atae UtsunomiyaDepartment of Hematology, Imamura Bun-in Hospital, Kagoshima, Japan.
Ki-Ryang KohDepartment of Hematology, Osaka General Hospital of West Japan Railway Company, Osaka, Japan.
Masao OgataBlood Transfusion Center, Oita University Faculty of Medicine, Oita, Japan.
Kisato NosakaDepartment of Hematology, Kumamoto University of Medicine, Kumamoto, Japan.
Kaoru UchimaruDepartment of Hematology/Oncology, Research Hospital, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Masako IwanagaDepartment of Frontier Life Science, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Yasuko SagaraJapanese Red Cross Kyushu Block Blood Center, Fukuoka, Japan.
Yoshihisa YamanoDepartment of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan.
Masahiro SatakeCentral Blood Institute, Blood Service Headquarters, Japanese Red Cross Society, Tokyo, Japan.
Akihiko OkayamaDepartment of Rheumatology, Infectious Diseases and Laboratory Medicine, University of Miyazaki, Miyazaki, Japan.
Manabu MochizukiDepartment of Ophthalmology and Visual Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
Shuji IzumoDivision of Molecular Pathology, Center for Chronic Viral Diseases, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
Shigeru SaitoDepartment of Obstetrics and Gynecology, University of Toyama, Toyama, Japan.
Kazuo ItabashiDepartment of Pediatrics, Showa University School of Medicine, Tokyo, Japan.
Shimeru KamihiraNagasaki Harbor Medical Center, ITREC, Nagasaki, Japan.
Kazunari YamaguchiDepartment of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, Japan.
Toshiki WatanabeDepartment of Medical Genome Sciences, Laboratory of Tumor Cell Biology, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
Isao HamaguchiDepartment of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, Japan 130hama@niid.go.jp.
National Institute of Infectious Diseases · JPThe University of Tokyo · JPJapanese Red Cross Society, Japan · JPNagasaki University · JPKagoshima University · JPSRL (Japan) · JPSt. Marianna University School of Medicine · JPUniversity of Miyazaki · JPImamura Hospital · JPJapanese Red Cross Fukuoka Hospital · JPKumamoto University · JPNagasaki Medical Center · JPOita University · JPShowa University · JPTokyo Medical and Dental University · JPUniversity of Toyama · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Quantitative PCR (qPCR) analysis of human T-cell leukemia virus type 1 (HTLV-1) was used to assess the amount of HTLV-1 provirus DNA integrated into the genomic DNA of host blood cells. Accumulating evidence indicates that a high proviral load is one of the risk factors for the development of adult T-cell leukemia/lymphoma and HTLV-1-associated myelopathy/tropical spastic paraparesis. However, interlaboratory variability in qPCR results makes it difficult to assess the differences in reported proviral loads between laboratories. To remedy this situation, we attempted to minimize discrepancies between laboratories through standardization of HTLV-1 qPCR in a collaborative study. TL-Om1 cells that harbor the HTLV-1 provirus were serially diluted with peripheral blood mononuclear cells to prepare a candidate standard. By statistically evaluating the proviral loads of the standard and those determined using in-house qPCR methods at each laboratory, we determined the relative ratios of the measured values in the laboratories to the theoretical values of the TL-Om1 standard. The relative ratios of the laboratories ranged from 0.84 to 4.45. Next, we corrected the proviral loads of the clinical samples from HTLV-1 carriers using the relative ratio. As expected, the overall differences between the laboratories were reduced by half, from 7.4-fold to 3.8-fold on average, after applying the correction. HTLV-1 qPCR can be standardized using TL-Om1 cells as a standard and by determining the relative ratio of the measured to the theoretical standard values in each laboratory.

Indexed as

Cell Line, TumorDNA, ViralHTLV-I InfectionsHumansHuman T-lymphotropic virus 1JapanJurkat CellsLeukemia, T-CellLeukocytes, MononuclearProvirusesReal-Time Polymerase Chain ReactionViral LoadVirus IntegrationDNA, Viral

Identifiers

PMID26292315
PMCPMC4609719
OpenAlexW1199655332

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.